Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin. The company is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions.
APUS stock price ended at $0 on Wednesday, after dropping NaN%
On the latest trading day May 06, 2026, the stock price of APUS fell by NaN%, dropping from $NaN to $NaN. During the session, the stock saw a volatility of NaN%, with prices oscillating between a daily low of $NaN and a high of $NaN. On the latest trading day, the trading volume for APUS decreased by -- shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, -- shares were traded, with a market value of approximately --.
APUS Technical Signals
Technical Signals Summary
Buy Signals 0
Neutral Signals 7
Sell Signals 0
Strong Sell
Sell
Neutral
Buy
Strong Buy
APUS currently exhibits 0 buy signals and 0 sell signals. The stock has been in an downtrend since --, with a total price change of -- during this period. Overall, the technical indicators point to a Neutral outlook for the mid-term.
Bullish/Bearish Signals for APUS
Our algorithms analyze key indicators like moving averages, RSI, MACD, and trading volume to generate bullish and bearish signals for APUS. These insights help you make informed investment decisions.
Follow-Up Questions
How do technical analysis indicators apply to APUS?
According to technical analysis, Apimeds Pharmaceuticals US Inc has an aggregate signal of Neutral. Apimeds Pharmaceuticals US Inc has 0 Buy signals, 7 Neutral Signals and 0 sell signals.
What is the RSI for Apimeds Pharmaceuticals US Inc?
The RSI for Apimeds Pharmaceuticals US Inc is currently 0, indicating a neutral condition
What is Apimeds Pharmaceuticals US Inc price for the next 12 months?
Apimeds Pharmaceuticals US Inc APUS price for the next 12 months is estimated at $0.
How high is Apimeds Pharmaceuticals US Inc expected to go?
According to wall street analysts, Apimeds Pharmaceuticals US Inc is expected to reach a high forecast of $0.